Abstract 239P
Background
Among patients [pts] with early-stage HR+, HER2- breast cancer [BC], this study aimed to measure associations of clinical characteristics, pts’ perception of treatment [tx] goals and endocrine therapy [ET] history on pts’ health-related quality of life [HRQoL].
Methods
A multinational (France, Germany, Italy, Spain, UK, Japan and US) survey of pts diagnosed [dx] with stage I-III HR+, HER2- BC was conducted from June to October 2019. Pts identified by their physician were invited to complete a pen and paper questionnaire that included the FACT-G and questions on awareness of tx goals. Four separate multivariable linear regression analysis were conducted to measure the association between patients’ clinical characteristics and ET history on each of the 4 FACT-G domain scores: Physical Wellbeing [PWB], Social/Family Wellbeing [SWB], Emotional Wellbeing [EWB] and Functional Wellbeing [FWB]. Regression coefficients are reported where p values <0.05. A positive coefficient implies higher HRQoL.
Results
1152 pts were recruited by 320 physicians. PWB (n=1030) score was impacted if pts completed ET ≤6 months and >6 months before data collection (+2.87, +3.16), if BC dx Stage IIIA or IIIB/C (-2.32 and -2.38) and if pts felt goal of their tx was to stop BC from progressing (-3.00). SWB (n=1029) score was impacted if pt currently receiving tamoxifen (+2.02), if BC dx Stage IIIB/C (-2.69) and if pts felt goal of their tx was to prevent BC returning after surgery (+1.19). EWB (n=1033) score was impacted by time since dx (+0.001), if BC dx Stage IIIB/C (-1.87), or if pts felt goal of their tx was to stop BC from progressing (-2.94). FWB (n=1034) score was impacted if pts were older (-0.10), by time since dx (+0.002), if pre/peri-menopausal (-1.76), if BC dx Stage IIA, IIIA or IIIB/C (-2.18, -3.09, -4.07), if pts felt goal of their tx was to stop BC from progressing (-2.65) or increase length of life (-1.16).
Conclusions
The 4 FACT-G HRQoL domain scores were impacted by stage of BC at diagnosis, ET history and pt perception of tx goals. This suggests that earlier diagnosis and positive reinforcement of tx goals could have a positive impact on HRQoL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Adelphi Real World.
Funding
Eli Lilly and Company.
Disclosure
R. Williams: Honoraria (institution), Eli Lilly have paid Adelphi Real World a fee for conducting this research and drafting this abstract: Eli Lilly and Company. J. Brown: Shareholder/Stockholder/Stock options, Full/Part-time employment: Eli Lilly and Company. A. Rider: Honoraria (institution), Eli Lilly have paid Adelphi Real World a fee for conducting this research and drafting this abstract: Eli Lilly and Company. R. Wild: Honoraria (institution), Eli Lilly have paid Adelphi Real World a fee for conducting this research and drafting this abstract: Eli Lilly and Company. E. Clayton: Honoraria (institution), Eli Lilly have paid Adelphi Real World a fee for conducting this research and drafting this abstract: Eli Lilly and Company. M. Method: Shareholder/Stockholder/Stock options, Full/Part-time employment: Eli Lilly and Company.